TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30706508
Drug: Metronidazole (MTZ)
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole (MTZ) 500 mg
Study: 30706508
Drug: NIC gum
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NIC gum 2 mg
Study: 26356396
Drug: L-lysine aescinat
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-lysine aescinat
Study: 23256139
Drug: VA-fortified milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: VA-fortified milk (250 mL daily providing 196 retinol equivalents/d) for 3 months
Study: 21277984
Drug: Naloxone (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.15 mg/kg)
Study: 28132005
Drug: Low energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low energy shock wave therapy plus eccentric exercises
Study: 28132005
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment plus eccentric exercises
Study: 23946609
Drug: Milligan‐Morgan hemorrhoidectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milligan‐Morgan hemorrhoidectomy with anal cushion suspension and partial internal sphincter resection
Study: 16686958
Drug: Low-dose Cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose Cisplatin, 5-Fluorouracil and Interferon alpha with external beam radiation
Study: 2935094
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV insulin infusion of 2.5 U/h (Group B)
Study: 2935094
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV insulin infusion of 5.0 U/h (Group C)
Study: 2935094
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV insulin infusion of 7.5 U/h (Group D)
Study: 2935094
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV insulin infusion of 10.0 U/h (Group E)
Study: 2935094
Drug: No insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No insulin given (Non-diabetic patients - NDP)
Study: 2935094
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV insulin infusion of 2.5 U/h in a patient with advanced chronic renal failure (CRF)
Study: 12780979
Drug: Intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous salbutamol (15 &micro;g/kg)
Study: 10734512
Drug: Perfloxacin 400
Normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfloxacin 400 mg bd twice a day for five days
Study: 10734512
Drug: Ofloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 200 mg bd twice a day for five days
Study: 1954153
Drug: Ethanol at
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol at 0.66 g EtOH/kg body weight
Study: 6941640
Drug: alpha‐beta‐blocker (labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐beta‐blocker (labetalol 300 mg b.d.)
Study: 6941640
Drug: alpha‐beta‐blocker (propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐beta‐blocker (propranolol 80 mg b.d.)
Study: 17631737
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy and stretching exercises (LSG, n=10)
Study: 12413614
Drug: Cyclic transdermal
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic transdermal 17‐beta estradiol (0.10 mg/day, Climara)
Study: 8593018
Drug: Isepamicin 15
Normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin 15 mg/kg once daily for 10 days
Study: 2649123
Drug: Extradural 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural 0.5% bupivacaine with additional morphine (bolus 4 mg plus 0.5 mg h‐1)
Study: 2649123
Drug: Extradural 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural 0.5% bupivacaine without morphine
Study: 367851
Drug: Levamisole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (2.5 mg/kg body weight on 2 consecutive days/week for 3 months)
Study: 29052236
Drug: Delayed therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed therapy ICD programming (Arm C)
Study: 26458923
Drug: Adapted Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted Physical Activity (APA) program (aerobic and resistance exercises) in addition to usual care (including chemotherapy at the investigator's choice)
Study: 26458923
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (including chemotherapy at the investigator's choice)
Study: 19219907
Drug: Newly developed
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly developed compound for the treatment of osteoarthritis and rheumatoid arthritis
Study: 18551937
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of botulinum toxin type‐A (BTX‐A)
Study: 15588742
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate infusion
Study: 9018020
Drug: tianeptine (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: tianeptine (25-50 mg/day)
Study: 3007605
Drug: Captopril (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (100 mg orally)
Study: 3007605
Drug: HOE 498
Normalized name: CASTOR OIL 3 mg in 30 mg / ROSEMARY 4.5 mg in 30 mg / TOCOPHEROL 9 mg in 30 mg TOPICAL LIQUID [HOEGOA Herbal Hair Growth OiI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOE 498 (10 mg orally)
Study: 30545333
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment of the mother including psychotherapy and pharmacotherapy (Step 1 treatment group)
Study: 20868962
Drug: 0.03 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg/kg neostigmine
Study: 20868962
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg neostigmine
Study: 18037627
Drug: Everolimus (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (6 mg/day)
Study: 2577377
Drug: Ebastine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine (10 mg daily escalating to 40 mg daily)
Study: 1103017
Drug: S‐Adenosylmethionine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐Adenosylmethionine (25 mg i.m. three times daily)
Study: 1103017
Drug: Imipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (25 mg i.m. three times daily)
Study: 21320119
Drug: Levetiracetam (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (up to 30 mg/kg/day)
Study: 19229821
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 1,000 IU/day
Study: 11456011
Drug: Levocabastine 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine 0.05% ophthalmic suspension
Study: 8426198
Drug: Recent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent treatment protocols (H1, H2, H5)
Study: 3304382
Drug: Calcitonin (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin (i.v. 1.5 i.u. kg‐1 body mass bolus or 10 i.u. followed by infusion to overall 1.5 i.u. kg‐1 body mass dose)
Study: 31752829
Drug: BV juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: BV juice (480 ml/day)
Study: 31752829
Drug: Placebo (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (480 ml/day)
Study: 21269547
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g EPH (egg-protein hydrolysate)
Study: 21269547
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g EPH
Study: 21269547
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g EPH
Study: 21269547
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g EPH with 2 g MP (milk protein)
Study: 21269547
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g MP
Study: 16952781
Drug: Oxypurinol 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxypurinol 600 mg/day for 1 month
Study: 11149473
Drug: Single iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single iv infusion of 90 mg of pamidronate (group A)
Study: 11149473
Drug: First infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First infusion of 90 mg of pamidronate followed by 30 mg every 3 months (group B)
Study: 8136741
Drug: 1 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg/day of ambisome
Study: 3119786
Drug: Recombinant DNA‐produced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA‐produced gamma‐interferon (3, 30, 300, 1,000, or 3,000 micrograms/m2) administered intravenously over two hours
Study: 3119786
Drug: Recombinant DNA‐produced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA‐produced gamma‐interferon (1,000 micrograms/m2) administered continuously over 24 hours
Study: 3119786
Drug: Recombinant DNA‐produced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA‐produced gamma‐interferon (1,000 micrograms/m2) administered daily either by two or 24 hour infusion for 14 days
Study: 29451869
Drug: Gel head
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel head pad (Control)
Study: 27531486
Drug: Mecobalamin tablets
Normalized name: mecobalamin Oral Tablet
DrugBank: Mecobalamin (DB03614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mecobalamin tablets and glutathione injection during chemotherapy
Study: 27531486
Drug: Glutathione injection
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione injection only
Study: 22430274
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg/d for 4 weeks followed by 2 weeks off treatment (schedule 4/2)
Study: 22430274
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg/d on the continuous daily dosing (CDD) schedule
Study: 17707978
Drug: Phytostanol supplementation
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytostanol supplementation (1.6 g of free phytostanol equivalents as phytostanol ester, 2.7 g stanol esters)
Study: 10960756
Drug: Clearfil Liner
Normalized name: linerixibat
DrugBank: Linerixibat (DB11729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clearfil Liner Bond 2V after K-etchant (40% phosphoric acid gel) pre-conditioning
Study: 8982778
Drug: Peptide immunotherapy
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide immunotherapy (IPC-1 and IPC-2, 250 micrograms, s.c. injections weekly for 4 weeks)
Study: 8982778
Drug: Peptide immunotherapy
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide immunotherapy
Study: 1451645
Drug: L-carnitine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (30 mg/kg)
Study: 6431573
Drug: 0.5-mg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-mg oral dose of brotizolam
Study: 30887937
Drug: Green banana
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green banana biomass (40 g) (RS: approximately 4·5 g)
Study: 30086659
Drug: Group-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based cognitive behavioral therapy (CBT) stress management program
Study: 26968269
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol alone (0.03 ml/kg/dose)
Study: 26968269
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol with ipratropium bromide (250 ug/dose)
Study: 25224654
Drug: Steroid-eluting bioabsorbable
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-eluting bioabsorbable implant placed in the office after ESS
Study: 25224654
Drug: Steroid-eluting bioabsorbable
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-eluting bioabsorbable implant
Study: 22785573
Drug: Amlodipine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine combination regimen
Study: 19288975
Drug: Riluzole (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (100-200 mg/d)
Study: 17694684
Drug: Supplemental magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental magnesium infusion (2 g after induction of anesthesia, then 8 g upon arrival in ICU until 24 hr)
Study: 16979991
Drug: MMF 1.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 1.35 +/- 0.23 g/d (group 1)
Study: 16979991
Drug: MMF 2
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 2 g/d (group 2)
Study: 10563400
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g meropenem tds
Study: 10563400
Drug: amikacin 15
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: amikacin 15 mg/kg single dose daily plus ceftazidime 2 g tds
Study: 8894145
Drug: Pamidronate disodium
Normalized name: Pamidronate Disodium
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate disodium (120 mg for Group I, 180 mg for Group II, 240 mg for Group III) with daily infusions of either 30 mg or 60 mg for 2 years.
Study: 8894145
Drug: Pamidronate disodium
Normalized name: Pamidronate Disodium
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate disodium (60 mg infusions) for 2 years.
Study: 8894145
Drug: Pamidronate disodium
Normalized name: Pamidronate Disodium
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate disodium treatment.
Study: 6395060
Drug: Silicone sponge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone sponge soaked in antibiotic solution for at least 30 minutes prior to insertion
Study: 6395060
Drug: Silicone sponge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone sponge not soaked in antibiotic solution
Study: 26703193
Drug: Intravenous Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Tranexamic Acid (IV TXA) 2 g
Study: 26703193
Drug: Topical Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Tranexamic Acid (Topical TXA) 2 g
Study: 26703193
Drug: Topical Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Tranexamic Acid (Topical TXA)
Study: 26703193
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and Topical Tranexamic Acid
Study: 25234206
Drug: Blood-pressure-lowering treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood-pressure-lowering treatment (perindopril and indapamide)
Study: 22072050
Drug: Adjuvant radioactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radioactive iodine treatment
Study: 22072050
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant radioactive iodine treatment
Study: 19284641
Drug: Hyperbaric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric treatment at 1.3 atm and 24% oxygen (treatment group, n = 33)
Study: 17542615
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g dose of steamed red cabbage
Study: 17542615
Drug: 300 g
Normalized name: Zantac 300 GELdose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 g dose of steamed red cabbage
Study: 27206914
Drug: 35% phosphoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% phosphoric acid treatment
Study: 11356211
Drug: Er‐YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er‐YAG laser treatment at 2Hz and 250mJ on dentin and 300mJ on enamel
Study: 11356211
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment followed by acid etching
Study: 7884663
Drug: Cabergoline tablets
Normalized name: Cabergoline Tablets
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline tablets (1‐mg single oral dose)
Study: 7884663
Drug: Cabergoline solution
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline solution (1‐mg single oral dose)
Study: 7884663
Drug: Cabergoline tablets
Normalized name: Cabergoline Tablets
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline tablets
Study: 7884663
Drug: Cabergoline solution
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline solution
Study: 7884663
Drug: Cabergoline tablets
Normalized name: Cabergoline Tablets
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline tablets vs solution
Study: 2874821
Drug: Felodipine 5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5‐20 mg twice daily
Study: 2874821
Drug: Hydralazine 25‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine 25‐100 mg twice daily
Study: 26614823
Drug: Short-term oral
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term oral ranolazine 500-1000 mg twice daily for 2 weeks
Study: 24783602
Drug: Counting group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counting group (patients instructed to count numbers backwards starting from 100 during propofol injection)
Study: 24121454
Drug: Goshajinkigan (TJ-107)
Normalized name: TJ-CD4B/ABL111
DrugBank: Givastomig (DB18618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goshajinkigan (TJ-107) 7.5 g daily
Study: 21148246
Drug: Prescribed dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed dietary phosphate restriction (≤ 870 mg, 871 to 999 mg, 1000 mg, 1001 to 2000 mg)
Study: 11109471
Drug: Cesar therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cesar therapy
Study: 11109471
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment by general practitioner
Study: 29624254
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release nimesulide formulation
Study: 29624254
Drug: Reference nimesulide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference nimesulide formulation
Study: 26245847
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with no additional training
Study: 24673496
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg luseogliflozin
Study: 24673496
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg luseogliflozin
Study: 24673496
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg luseogliflozin
Study: 24673496
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg luseogliflozin
Study: 21566204
Drug: L‐NMMA (6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA (6.4 µmol/min)
Study: 21566204
Drug: L‐NMMA in
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA in PGF(2α)‐preconstricted veins
Study: 19142567
Drug: EPA&DHA (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA&DHA (daily DHA/EPA capsules)
Study: 19142567
Drug: Fatty fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatty fish (150 g salmon, three times per week)
Study: 19142567
Drug: Lean fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lean fish (150 g cod, three times per week)
Study: 12623959
Drug: felodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: felodipine (10 mg/d, n=14)
Study: 12623959
Drug: lercanidipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: lercanidipine (10 mg/d, n=14)
Study: 12623959
Drug: acute drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: acute drug administration
Study: 10519687
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of brief advice and health education literature
Study: 8901795
Drug: 10.5 mg
Normalized name: pectin 10.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.5 mg pure acetylsalicylic acid
Study: 8901795
Drug: 9.1 mg
Normalized name: menthol 9.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.1 mg salicylic acid
Study: 1912752
Drug: Fixed (non-negotiable)
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed (non-negotiable) dose reduction schedule
Study: 7120089
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg perphenazine tablet
Study: 7120089
Drug: Two 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 8 mg perphenazine tablets
Study: 7120089
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg amitriptyline tablet
Study: 7120089
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg amitriptyline tablet with 10 mg amitriptyline and 4 mg perphenazine combination tablet
Study: 7120089
Drug: Two combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two combination tablets (10 mg amitriptyline and 4 mg perphenazine each)
Study: 28695660
Drug: Menthacarin (2×1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menthacarin (2×1 capsule/day for 4 weeks)
Study: 28695660
Drug: Placebo (2×1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2×1 capsule/day for 4 weeks)
Study: 25544635
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in both anterior and posterior regions